Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Artelo Biosciences Inc ARTL

Healthcare
Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system (ECS), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body. It is developing a dual cannabinoid agonist for the G protein-coupled receptor (GPCR) that targets a synthetic small molecule program, ART27.13, as a potential treatment for anorexia associated with cancer. Its second program ART26.12, is a small molecule lead product candidate from its platform of inhibitors of fatty acid binding proteins, notably Fatty Acid Binding Protein 5 (FABP5), which is undergoing pre-clinical research as a potential cancer therapeutic, for pain and inflammation, and in anxiety-related disorders, including post-traumatic stress disorder. In addition, the Company is also developing ART12.11 (CBD cocrystal), a solid-state composition of cannabidiol (CBD).


NDAQ:ARTL - Post by User

Artelo Biosciences Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(3)
•••
Post by lemonn8buckon Nov 22, 2021 8:13am
151 Views
Post# 34151971

A TRUE HIDDEN GEM

A TRUE HIDDEN GEMHard to believe there are no recent posts on this one. There is a youtube interview of the CEO in which he claims a pre-clinical study showed 50 healthy patients showed the effect of weight gaining from ART27.13 in a 12 day period with a p value of  0.0005.

So they know the drug works, its not explained by chance at all, and they have patents on it. The quesiton now is, does it work in patients going through cancer anorexia?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities